You are here

Using smokeless tobacco

Document

Malignant neoplasm of the pancreas - Using smokeless tobacco Factor

Last reviewed for CCPS 30 November 2013.

Investigative Documents

Claimant Report - Use of Smokeless Tobacco - Malignant Neoplasm of the Pancreas [CR9256]

Preliminary questions [35667]

35670

there is some evidence that the use of smokeless tobacco may be a factor in the development of the condition under consideration.

35671 the veteran has engaged in the use of smokeless tobacco on more days than not for an extended period at some time.

35672the veteran has established the causal connection between the use of smokeless tobacco and VEA service for the clinical onset of malignant neoplasm of the pancreas.

35673the veteran has established the causal connection between the use of smokeless tobacco and operational service for the clinical onset of malignant neoplasm of the pancreas.

or

35674the veteran has established the causal connection between the use of smokeless tobacco and eligible service for the clinical onset of malignant neoplasm of the pancreas.

Clinical onset and operational service [35673]

35675

the veteran used smokeless tobacco on more days than not for at least twenty years before the clinical onset of the condition under consideration, and the clinical onset occurred within the twenty years following that period.

35677

operational service made a material contribution to the veteran's use of smokeless tobacco on more days than not for at least twenty years before the clinical onset of the condition under consideration, where the clinical onset occurred within the twenty years following that period.

Clinical onset and eligible service [35674]

35676

the veteran used smokeless tobacco on more days than not for at least thirty years before the clinical onset of the condition under consideration, and the clinical onset occurred within the fifteen years following that period.

35678

eligible service made a material contribution to the veteran's use of smokeless tobacco on more days than not for at least thirty years before the clinical onset of the condition under consideration, where the clinical onset occurred within the fifteen years following that period.